

Targeting-the-Kinome Symposium
December 3 – 6, 2006

Programme as of 15th November 2006

Sunday, 3rd December 2006

14.00 – 19.00 Registration / Poster set-up and Poster session
18.00 – 20.00 Reception and Opening Aperó

Monday, 4th December 2006

Session I Chair: Dr. Brian A. Hemmings, Friedrich Miescher Institute for Biomedical Research, Basel

08.30 – 09.00 Opening Ceremony

09.00 – 09.40 Prof. Tony Hunter, The Salk Institute, La Jolla, CA, USA
The history of the kinome and its use to develop inhibitors

09.40 – 10.20 Prof. Tony Pawson, Samuel Lunenfeld Research Institute, Toronto, ON, Canada
Kinome signalling through regulated protein-protein interactions in normal and cancer cells

10.20 – 10.50 Coffee

Session II Chair: Prof. Paul Herrling, Head Corporate Research, Novartis International, Basel, Switzerland

10.50 – 11.30 Prof. Axel Ullrich, Max-Planck-Institute for Biochemistry, Martinsried, Germany
Mining the oncokinome 20 years plus: per aspera ad astra of cancer therapy

11.30 – 12.10 Prof. Joseph Schlessinger, Yale University School of Medicine, New Haven, CT, USA
Cell signaling by receptor tyrosine kinases: from bench to bedside

12.10 – 12.50 Prof. Nancy E. Hynes, Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
Targeting the ErbB receptors in cancer

13.00 – 14.30 Lunch

Session III Chair: Dr. Elisabeth Buchdunger, Novartis Institutes for BioMedical Research, Basel, Switzerland

14.30 – 15.10 Dr. Kari Alitalo, University of Helsinki, Helsinki, Finland
VEGFs and receptors involved in angiogenesis versus lymphangiogenesis

15.10 – 15.50 Prof. Carl-Henrik Heldin, Ludwig Institute for Cancer Research, Uppsala, Sweden
Signalling via receptors for PDGF and TGF-beta - possible targets for tumor therapy

15.50 – 16.30 Prof. Sir Philip Cohen, MRC, University of Dundee, Scotland, UK
Targeting protein kinases for the development of anti-inflammatory drugs

16.30 – 17.00 Coffee

Targeting-the-Kinome Symposium
December 3 – 6, 2006

Session IV	Chair: Prof. Bernd Groner, Georg Speyer House, Institute for Biomedical Research, Frankfurt am Main, Germany
17.00 – 17.40	Dr. Nick Lydon, Granite Biopharma LLC, Wilson, WY, USA From Gleevec to targeting the kinome
17.40 – 18.20	Dr. Paul Manley, Novartis Institutes for BioMedical Research, Basel, Switzerland Nilotinib: A new Bcr-Abl kinase inhibitor for the treatment of imatinib-resistant CML and GIST
18.20 – 19.00	Prof. Alex Matter, Novartis Institute for Tropical Diseases (NITD), Singapore, Singapore Kinases as drug targets in infectious diseases
19.00 – 21.00	Poster session

Tuesday, 5th December 2006

Session V	Chair: Christoph Moroni, Department Clinical-Biological Sciences, University of Basel, Basel, Switzerland
08.30 – 09.10	Prof. George Demetri, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA Treating the kinase signalling addiction in solid tumors: lessons learned from GIST as a paradigm of molecularly targeted therapy
09.10 – 09.50	Prof. Alexander Levitzki, The Hebrew University of Jerusalem, Israel Targeting the EGFR and the PKB pathway
09.50 – 10.30	Prof. Sara A. Courtneidge, The Burnham Institute, La Jolla, CA, USA The involvement of Src and its substrates in cancer cell invasion
10.30 – 11.00	Coffee
Session VI	Chair: Prof. Prof. Max M. Burger, Chairman Novartis Science Board, Novartis International, Basel, Switzerland
11.00 – 11.40	Prof. Owen Witte, University of California, Los Angeles, CA, USA Modeling prostate cancer progression and therapy by tissue regeneration
11.40 – 12.20	Prof. James A. Fagin, Memorial Sloan-Kettering Cancer Center, New York, NY, USA Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets
12.20 – 13.00	Prof. David Livingston, Dana-Farber Cancer Institute, Boston, MA, USA Kinase shRNA screening in fresh, primary human ovarian cancer cells
13.00 – 14.30	Lunch

Targeting-the-Kinome Symposium
December 3 – 6, 2006

- Session VII** Chair: Prof. Georges-A. Hollaender, Department Clinical-Biological Sciences, University of Basel, Basel, Switzerland
- 14.30 – 15.10 Prof. Mariano Barbacid, Spanish National Cancer Center (CNIO), Madrid, Spain
CDKs and the cell cycle
- 15.10 – 15.50 Prof. Adrian Merlo, University Hospital, Basel, Switzerland
Translating biology into clinics: the case of glioblastoma
- 15.50 – 16.30 Prof. Radek Skoda, Department Clinical-Biological Sciences, University of Basel, Switzerland
Mutated JAK2 and myeloproliferative disorders
- 16.30 – 17.00 Coffee
- Session VIII** Chair: Prof. Ruth Chiquet, Friedrich Miescher Institute For Biomedical Research, Basel, Switzerland
- 17.00 – 17.40 Prof. Bill Sellers, Novartis Institutes for BioMedical Research, Cambridge, MA, USA
Linking somatic genetics alterations in cancer to therapeutics
- 17.40 – 18.20 Prof. Michael Stratton, Wellcome Trust Sanger Institute, Hinxton, UK
Screen of the full protein kinase gene family for somatic mutations
- 18.20 – 19.00 Prof. Victor Velculescu, John Hopkins University School of Medicine, Baltimore, MD, USA
Genomic analysis of human cancer
- 19.00 – 21.00 Poster session

Wednesday, 6th December 2006

- Session IX** Chair: Dr. Juerg Zimmermann, Novartis Institutes for BioMedical Research, Basel, Switzerland
- 08.30 – 09.10 Dr. Carlos Garcia-Echeverria, Novartis Institutes for BioMedical Research, Basel, Switzerland
Blocking the IGF-IR/PI3K survival signalling pathway in cancer cells
- 09.10 – 09.50 Prof. Thomas M. Roberts, Dana-Farber Cancer Institute, Boston, MA, USA
Targeting PI3 kinase in cancer
- 09.50 – 10.30 Prof. David Barford, Institute of Cancer Research, London, UK
Structural basis for activation of B-RAF by oncogenic mutations and PKB/Akt by phosphorylation
- 10.30 – 11.00 Coffee

Targeting-the-Kinome Symposium
December 3 – 6, 2006

Session X	Chair: Prof. Matthias Wymann, Department Clinical-Biological Sciences, University of Basel, Switzerland
11.00 – 11.40	Prof. Mike Hall, Biozentrum, University of Basel, Basel, Switzerland TOR signalling and control of cell growth
11.40 – 12.20	Prof. George Thomas, Genome Research Institute, University of Cincinnati Medical School, Cincinnati, OH, USA Targeting TSC with RAD001: The TSC1/2 tumor suppressor and proto-oncogene Rheb in mTOR signalling
12.20 – 13.00	Dr. Heidi Lane, Novartis Institutes for BioMedical Research, Basel, Switzerland A review of the potential of mTOR inhibitors for the treatment of human cancer
13.00 – 14.00	Lunch
Session XI	Chair: Dr Jan Hofsteenge, Friedrich Miescher Institute For Biomedical Research, Basel, Switzerland
14.00 – 14.40	Prof. Michael B. Yaffe, Massachusetts Institute of Technology, Cambridge, MA, USA A novel cell cycle checkpoint kinase pathway that integrates global stress response's and DNA damage
14.40 – 15.20	Prof. Susan M. Gasser, Friedrich Miescher Institute For Biomedical Research, Basel, Switzerland ATR kinases at sites of DNA damage
15.20 – 16.00	Prof. Peter J. Parker, CRUK, London Research Institute, London, UK PKC epsilon controls the final committed step in cell division
16.00 – 16.40	Dr. Jürgen Wagner, Novartis Institutes for BioMedical Research, Basel, Switzerland Protein kinase C inhibition: a novel approach to prevent solid organ rejection
16.40 – 17.10	Coffee
Session XII	Chair: Prof. Kurt Ballmer-Hofer, Paul Scherrer Institute, Villigen, Switzerland
17.10 – 17.50	Dr. Sandra Jacob, Novartis Institutes for Biomedical Research, Basel, Switzerland Structural biology contributions to tyrosine kinase drug discovery projects
17.50 – 18.30	Dr. Pascal Furet, Novartis Institutes for BioMedical Research, Basel, Switzerland Protein kinase inhibitors by design
18.30 – 19.10	Dr. Dorian Fabbro, Novartis Institutes for Biomedical Research, Basel, Switzerland Multitargeted kinase inhibitors: an old concept with a new name?
19.10	Closing Party